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Background: Preeclampsia is a major cause of maternal and perinatal morbidity and mortality worldwide and
especially in Latin America. High quality evidence indicates that calcium supplementation during pregnancy
significantly reduces the incidence of preeclampsia and its consequences, including severe maternal morbidity and
death. Few studies have assessed the implementation of this intervention in clinical practice. The study aimed to
assess the proportion of pregnant women who received calcium supplements in Brazilian public antenatal care
clinics.
Methods: This cross-sectional study interviewed women waiting for antenatal care visits in 9 public clinics in 4
Brazilian cities in 2010-2012. Trained interviewers used a standardized anonymous questionnaire to collect socio
demographic and obstetric data, information on ingestion of dairy products and on prescriptions received during
current pregnancy.
Results: A total of 788 valid questionnaires were analyzed. Participants were young (mean age 25.9), mostly
multiparous (71.3%) and in the 2nd or 3rd trimesters of pregnancy at the time of interview (87.6%). Only 5.1%
(40/788) had received a prescription for calcium supplements. Based on their reported ingestion of dairy products,
the mean daily dietary calcium intake of the participants was 210 (+ 265) mg/day and over 90% consumed less
than 1 g of calcium/day.
Conclusions: Despite good quality evidence indicating the benefits of this practice especially for women with low
calcium diets, less than 6% of a sample of women receiving antenatal care in Brazilian public clinics received a
prescription for calcium supplements. There is an urgent need to upscale the implementation of this life-saving
intervention.
Keywords: Preeclampsia, Eclampsia, Calcium, Dietary supplements, Primary prevention, Calcium dietary, Developing
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Each year, almost 60,000 women die in the world due to
hypertensive disorders of pregnancy [1]. Hypertension is
the leading cause of maternal mortality (MM) in Latin
America [2,3]. According to the latest national estimates,
pre-eclampsia (PE) and eclampsia (E) are the single largest
contributors to the MM rate of Brazil, accounting for* Correspondence: ginecologia@terra.com.br
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reproduction in any medium, provided the orapproximately 20% of all maternal deaths in that country
[4]. Hypertensive disorders are also a major cause of
elective preterm births as well as perinatal morbidity
and mortality [5-7]. Each year, the Brazilian public
health system spends over $14 million US dollars in direct
costs for the treatment of PE/E, a substantial expenditure
for a developing country [8].
PE, defined as hypertension and proteinuria with on-
set in the 2nd half of pregnancy [9], affects 6-10% of all
pregnant women and 2-8% of them will develop severe
forms of the disease including eclampsia, characterizedal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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genesis of PE is not yet completely understood, existing
evidence indicates that the main initiating events are
placental hypoperfusion, increased production of in-
flammatory and anti-angiogenic mediators, followed by
systemic endothelial damage, disseminated vasospasm,
generalized tissue hypoperfusion and aggravation of pla-
cental ischemia, thus perpetuating the vicious cycle
[11-14]. Currently there is no effective treatment for
PE/E and delivery is the only option to halt the disease
process [15].
Over 30 years ago, observational studies identified an in-
verse relationship between maternal calcium (Ca) intake
and the incidence of PE [16,17]. Based on these findings, a
series of randomized controlled trials (RCT) were carried
out to evaluate the effectiveness of Ca supplementation
in the prevention of PE [18-20]. Over the last 15 years,
several systematic reviews pooled the results of these
trials, showing the benefits of this intervention [21-24].
According to a systematic review of individual data
from 12 RCTs which included over 15,000 participants,
Ca supplementation starting in the 2nd trimester of
pregnancy reduces the risk of developing PE by 64% and
the risk of MM or severe maternal morbidity by 20%, in
women with low dietary Ca intake, defined as less than
900 mg/day [25]. In 2011 the World Health Organization
(WHO) recognized Ca supplementation during pregnancy
as an effective intervention to prevent PE and to reduce
MM and recommended that women with low dietary
intake or at high risk for PE should receive 1.5-2.0 g of
Ca daily, starting in the 2nd trimester [26].
PE is associated with a large burden of morbidity and
mortality in low-resource settings, especially in Latin
America, and there is a body of high quality evidence in-
dicating the potential benefits of Ca supplementation in
pregnancy; yet the actual implementation of this inter-
vention into clinical practice has not been extensively in-
vestigated. In 2010 Silva et al. interviewed 250 high-risk
pregnant or post-partum Brazilian women and reported
that only 10% of them had received prescriptions for Ca
supplements during pregnancy [27]. We identified no
other publications assessing the antenatal prescription of
Ca to prevent PE. Our main objective was to assess the
proportion of women who received a prescription of Ca
supplements during pregnancy in a sample of Brazilian
public healthcare clinics.
Methods
This cross-sectional study interviewed women receiving
antenatal care in the public Brazilian healthcare system.
The interviews were performed between October 2010
and June 2012 in nine public healthcare clinics located
in four cities in different geographic regions of Brazil:
Coari (Amazonas state, north region, 3 clinics), Brasília(Federal District, central region, 1 clinic), Piripiri (Piauí
state, central region, 3 clinics) and Tubarão (Santa Catarina
state, southern region, 2 clinics).These clinics offered
free antenatal care to the general obstetric population,
i.e. mostly low and medium risk pregnant women. The
Brazilian national health system offers free antenatal
care to all women in the country and recommends the
use of folic acid and iron supplements to all pregnant
women. There is no national guideline on other sup-
plements during pregnancy. Calcium carbonate tablets
containing 500 mg of elemental Ca are distributed free
of charge by the national health system and dispensed
locally in any public healthcare center, to all patients
who have a medical prescription for this supplement.
Pregnant women carrying a live fetus, of any parity
and gestational age, booked for antenatal care at one of
the selected centers, and capable of answering an oral
questionnaire were considered eligible to participate.
Women waiting for their 1st antenatal care visit were ex-
cluded. Interviewers approached the women in the waiting
rooms of the health facilities during morning periods,
explained the objectives of the study and invited them to
participate. Participants who fulfilled the selection criteria
and agreed to participate were asked to sign an informed
consent form and then interviewed using a standardized
oral questionnaire. The questionnaire was designed
and tested by the authors and consisted of close and
open-ended questions to collect information on socio
demographic characteristics, obstetric history, current
pregnancy, usual dairy intake and medical prescrip-
tions received so far, including Ca supplementation.
The question on dairy consumption asked participants
what was their current usual intake of milk, cheese or
other milk products. The Brazilian food composition
table [28] was used to estimate the amount of dietary
Ca ingested by the participants based on their con-
sumption of dairy products. Dairy intake was con-
verted to estimated Ca intake based on the reported
ingestion of milk (one 200 ml cup =246 mg Ca) and
cheese (one 30 g slice = 282 mg Ca). To assess the ad-
equacy of Ca intake, the latest recommendations of the
Dietary Reference Intakes - DRI were used [29,30]. Ac-
cording to these recommendations, adult pregnant
women should have a daily Ca ingestion of 1,000 mg
and pregnant adolescents (14-18 years) should have a
daily ingestion of 1,300 mg. Pregnant women with an
average Ca intake < 900 mg/day are classified as having
a low dietary intake of Ca [25].
The interviews were anonymous, lasted an average of
10 minutes and were conducted individually and privately.
Participants were encouraged to check their antenatal care
booklet, which was in their hands at the time of the inter-
view, to confirm information given to the interviewer.
Women were informed that they could decline to answer
Table 1 Main characteristics and dietary calcium intake of
788 Brazilian pregnant women
Variable Values1
Age, years 25.9 (6.3)
Marital status
Married or living with partner 647 (82.1)
Single 127 (16.1)
Separated/divorced 14 (1.8)
Parity
0 226 (28.7)
1 245 (31.1)
2 or + 317 (40.2)
Unplanned pregnancy 440 (55.8)
Gestational age at the time of the interview
Mean (SD), weeks 24.3 (8.3)
1st trimester 98 (12.4)
2nd trimester 315 (40.0)
3rd trimester 375 (47.6)
Number of antenatal care visits up to the moment
1 112 (14.2)
2 to 4 314 (39.9)
5 or + 362 (45.9)
Women at high risk for PE* 250 (31.7)
Current milk intake (cups/day)
0 189 (24.0)
1 (246 mg)2 282 (35.8)
2 - 3 (492 mg – 738 mg) 267 (33.9)
4 or + (984 mg or +) 50 (6.3)
Current cheese intake
Up to 1 portion3/day 130 (16.5)
Up to 1 portion/week 199 (25.3)
Up to 1 portion/month 50 (6.3)
Rarely4 or never 409 (51.9)
*Any of the following: nulliparity, age <20 or >35 years, diabetes mellitus or
history of hypertension in a previous pregnancy.
1All values expressed as mean (SD) or N (%).
2Equivalent calcium value.
3One portion is 30 g of cheese.
4Less than one portion per month.
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answered questions were excluded from the analyses.
The interviewers were three medical students and nine
nutrition undergraduates who were specifically trained
for this study. The interviewers collected data daily
during an average of five weeks in each of the participat-
ing clinics.
Sample size was calculated using the frequency of Ca
prescription reported by Silva 2010 [27] of 10%. With an
absolute error of 2.5% and a significance level of 5%, a
sample of 553 participants was calculated. Considering
possible losses, the planned sample was 800 participants.
The cities and public healthcare clinics included in the
study were selected as a convenience sample.
The completed questionnaires were sent by mail to
the first author who entered the data into an electronic
database. Results are presented descriptively as frequencies
and percentages for categorical variables, and as means
and standard deviation (SD) for continuous variables.
Relevant outcomes are presented with their 95% confi-
dence intervals (CI).
Participants were divided in two subgroups according
to their risk for PE, based on widely accepted parameters
[31-34]. Participants with any of the following character-
istics were considered at high risk for PE: nulliparas,
women <20 or >35 years, diabetics (type 1 or 2) or
women with a history of hypertension in a previous
pregnancy. All other participants, i.e. those without any
of the previous characteristics, were classified as being at
low risk for PE. We analyzed possible differences in the
rate of Ca prescription between these two groups using
the Chi square test. P values < 0.05 were considered
significant. The software SPSS version 1.6 (IBM® SPSS®,
Chicago, U.S.A) was used for analyses.
The study was approved by São Paulo Federal University’s
ethics committee and all participants provided free
informed consent. The study complies with the ethical
principles of the Helsinki declaration.
Results
A total of 832 eligible women were invited to participate
and 32 declined. Of the 800 who agreed to answer the
questionnaire, 12 refused to answer five or more questions
and were excluded from the study, resulting in 788 valid
questionnaires included in the final analyses. Table 1
presents the main characteristics of the participants.
Age ranged from 13 to 42 years and 17.6% were adoles-
cents. Most participants were living with a partner
(82.1%), multiparous (71.3%) and reported that the current
pregnancy had not been planned (56%). Nearly 90% of
participants were interviewed in the 2nd or 3rd trimesters
of pregnancy and almost half of them had attended at least
five antenatal visits at the time of the interview. A total of
51 women (6.5%) smoked and 61 (7.7%) consumed alcoholat least once a week. A total of 250 (31.7%) women were
classified as being at high risk for PE, the main factor was
nulliparity.
Approximately 60% of the women reported that they
drank only up to one cup of milk (246 mg Ca) daily,
while only 6.3% drank four or more cups of milk daily
(95% CI 4.8% - 8.2%). Over half of the participants never
or rarely (less than once a month) ate cheese. The inges-
tion of other dairy products (including yogurt, sour cream
or cream spreads) was even less frequent, with 79% (622)
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than once a month. Only 3% (4/139) of the adolescents
included in the survey drank four or more cups of milk
per day (984 mg Ca) and 58.2% reported that they rarely
or never ate cheese. Based on their reported ingestion of
dairy products, the mean daily dietary Ca intake of the
788 participants was 210 (± 265) mg and over 90% con-
sumed less than 1 g of Ca/day. The mean daily dietary Ca
intake from dairy products reported by adolescents was
313 (± 262) mg.
Less than 6% (N = 40) of the participants (95% CI 3.7% -
6.8%) reported that they had received a prescription for
Ca supplements during their current pregnancy (Table 2).
There were no significant differences in the women at
high versus low risk for PE (5.2% versus 5.0%, respect-
ively). Most (60%) of the 40 women who had received a
Ca prescription did not know the reasons for this sup-
plementation; only three reported to have been told that
these tablets were to prevent problems related to high
blood pressure. Approximately one third of the partici-
pants (N = 252) had been advised by their physician to
increase the ingestion of dairy products during preg-
nancy. Over half (144/252) of these women received
instructions to drink a total of 1-2 glasses of milk/day,Table 2 Calcium prescription and advice on the ingestion
of dairy products received by 788 Brazilian pregnant
women
Values
N (%)
Did physician prescribe calcium?
Yes 40 (5.1)
No 694 (88.1)
Unsure/Doesn’t know 54 (6.8)
Did physician explain the reason for calcium
prescription2?
Yes 16 (40.0)
No 24 (60.0)
Reason for calcium prescription2:
For bones (baby or mother) 10 (62.5)
For blood pressure 3 (18.8)
Calcium deficiency 2 (12.5)
Anemia 1 (6.3)
Did physician tell you to eat more dairy products?
Yes 252 (32.0)
No 536 (68.0)
Recommendations given by physician2:
Drink 1–2 cups of milk/day 144 (57.1)
Drink 3–4 cups of milk/day 10 (4.0)
Unclear/did not specify 98 (38.9)
2Over total answering Yes to previous question.while approximately 40% (98/252) informed that their
doctor had not been clear about the type and quantity
of dairy product that they should consume daily (Table 2).
Overall, less than 1% of the participants (4/788) were
encouraged to consume enough dairy products to attain
international DRIs for pregnant women.
Discussion
Less than 6% of almost 800 women receiving antenatal
care in nine public Brazilian healthcare clinics were
given a prescription of Ca supplements during preg-
nancy and most of them did not know why they were
taking it. Additionally, based on their reported dairy
product ingestion, over 90% of the participants con-
sumed less than 1 g Ca/day. Less than one third of the
women informed that their physicians had told them to
increase the ingestion of these products during preg-
nancy and when they did, in over 95% of the cases, the
recommendations did not comply with minimum DRIs
for pregnancy.
Although our main objective was not to estimate dietary
intake of Ca by pregnant women, the participants’ average
dietary Ca intake from dairy products was less than
400 mg/day. Given that milk products were the only food
items included in the questionnaire, the actual daily Ca
intake of these women was probably higher than this,
although it is unlikely that it would be close to the 1 g/day
recommended for pregnancy. According to the latest
national food inquiry survey, the mean dietary Ca intake
of adult Brazilian women (19-59 years) is only 438 mg/day
and 90.7% of them do not reach the recommended dietary
calcium intake for their age [35]. According to this same
survey, dairy products are the main source of dietary Ca
for Brazilian adults. Only a few, small studies have
assessed the Ca ingestion of Brazilian pregnant women
and they focused on specific groups, such as overweight
and adolescent participants. According to these studies,
mean daily Ca intakes ranged from 586.6 mg to 842.9 mg/
day [36-38]. This low dietary Ca intake is typical of diets
in Latin America and Asia [39-41] and contrasts with the
daily 1200 mg Ca/day of American [42] and European
pregnant women [43,44], with some exceptions [45].
The only other study that evaluated Ca prescription to
prevent PE was also carried out in Brazil and reported
that 10% of 250 women at high risk for PE had received
Ca supplements during pregnancy [27]. The somewhat
higher proportion of women receiving Ca supplementa-
tion in that study could be attributed to the fact that those
investigators interviewed exclusively high-risk women
managed in tertiary teaching university hospitals.
This study had several strong points. To the best of our
knowledge, it is the largest study to analyze Ca supple-
mentation during pregnancy to prevent PE. In addition,
data collection followed rigorous methodology using a
Camargo et al. BMC Pregnancy and Childbirth 2013, 13:206 Page 5 of 7
http://www.biomedcentral.com/1471-2393/13/206standardized anonymous questionnaire and trained inter-
viewers. However, we acknowledge that the assessment of
dietary Ca could have been more complete if we had col-
lected information on the ingestion of other non-dairy
sources of Ca. A limitation of this study was the use of a
convenience sample. However, the main characteristics of
our participants are similar to the general population of
Brazilian reproductive age women reported in a recent
national survey on maternal and child health [46]. Never-
theless, the results of this survey cannot be generalized to
other settings or countries. Although our sample most
likely over-represented urban women, it would be ex-
pected that the dietary Ca intake of pregnant rural women
would be even lower, as suggested by the latest national
inquiry on food habits [35]. Finally, as with any other
patient survey, the data analyzed were based exclusively
on the answers given by the participants and are therefore
subject to recall bias [47] and do not necessarily reflect
the exact practice of the physicians. Future studies should
interview health professionals involved in prenatal care, to
assess their knowledge, attitude and practice regarding Ca
supplementation during pregnancy, in order to identify
the main facilitators and barriers to upscale the implemen-
tation of this intervention.
Our findings indicate that Brazilian doctors working in
the public health system do not routinely prescribe Ca
to their pregnant patients, despite the free availability of
these supplements in the public health system. This is
possibly due to their lack of knowledge about the benefits
of Ca supplementation to prevent PE. Besides the need for
continued medical education of these professionals, the
guidelines currently used in the country’s public health
care system need to be reviewed and updated, to encour-
age the use of this, as well as other evidence-based inter-
ventions for maternal health. Besides the evident benefits
of Ca supplementation for the individual patients and
their families, decreasing the number of cases of PE/E
can also have significant cost saving implications for the
national public health system.
Most of the research to date has focused on supple-
mentation starting in the 2nd trimester of pregnancy
and although current evidence supports Ca supplemen-
tation during pregnancy for the prevention of PE, it has
been hypothesized that the effect could be even more
dramatic if supplementation started earlier. WHO is
currently coordinating a multi-country randomized trial
to assess if periconceptional Ca supplementation reduces
the incidence of recurrent PE more effectively than sup-
plementation starting in the 2nd trimester [48]. Results of
this trial may increase the value of Ca supplementation in
the future.
Despite existing WHO evidence-based recommenda-
tions indicating that Ca supplementation in pregnancy
is beneficial for women with low dietary Ca intake, ourstudy indicates that this intervention is not being used
in the daily practice of public healthcare clinics in
Brazil. This finding is not unexpected since the gap be-
tween good evidence and implementation is common in
the history of obstetric practice. For example, several
decades passed between the publication of systematic
reviews pointing that antenatal corticosteroids signifi-
cantly reduced mortality and morbidity of premature
babies, before this intervention was widely implemented
worldwide [49]. Similarly, it took almost a century, dur-
ing which thousands of unnecessary maternal deaths
occurred, until magnesium sulfate became widely used
for the prevention and treatment of eclampsia [50].
Implementation of evidence-based obstetrical practice
remains a challenge. Time, as well as political determin-
ation, strategic efforts, financial and human resources are
necessary to transform good evidence into good clinical
practice. Investments in implementation research are also
needed to develop strategies that will help to reduce the
still ubiquitous large gap between evidence and practice.
Conclusions
Ca supplementation is given to less than 6% of women
receiving antenatal care in a sample of public clinics in
Brazil. Strategic efforts are needed to enhance the imple-
mentation of this evidence-based intervention. Upscaling
this practice could lead to a significant reduction in the
incidence of PE/E, reducing associated maternal and
perinatal morbidity and mortality as well as costs for the
Brazilian public health system.
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